Literature DB >> 8236126

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.

A Branchi1, A Rovellini, D Sommariva, A G Gugliandolo, A Fasoli.   

Abstract

In order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were -16% with fenofibrate, -10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236126

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.

Authors:  A Ugur Ural; M Ilker Yilmaz; Ferit Avcu; Atilla Yalcin
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

Review 2.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 3.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 4.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 6.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

Authors:  C M Spencer; L B Barradell
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

8.  Influence of blood lipids on global coagulation test results.

Authors:  Jung-Ah Kim; Ji-Eun Kim; Sang Hoon Song; Hyun Kyung Kim
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

Review 9.  The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.

Authors:  Pavan Malur; Arthur Menezes; James J DiNicolantonio; James H O'Keefe; Carl J Lavie
Journal:  Mo Med       Date:  2017 Nov-Dec

Review 10.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.